Nephrol Dial Transplant (2000) 15: 487-497
© 2000 European Renal Association-European Dialysis and Transplant Association
The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics
The Section of Nephrology, Department of Medicine, Rush Medical College, Chicago, IL, 1 Division of Biostatistics, Department of Preventive Medicine, University of Iowa, Iowa City, IA, 2 Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA, 3 Monash Medical Centre, Clayton, Victoria, Australia and 4 University of Heidelberg, Heidelberg, Germany
Correspondence and offprint requests to: Roger A. Rodby, MD, Rush-Presbyterian St Luke's Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612, USA.
Background. Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world. Angiotensin-converting enzyme inhibitors have been demonstrated to be renoprotective in type I diabetes and are now the standard of care for both hypertensive and non-hypertensive type I diabetic patients with any level of proteinuria. The role of blockade of the renin–angiotensin system in type II diabetic patients is not defined. The Collaborative Study Group has initiated the Irbesartan Type II Diabetic Nephropathy Trial (IDNT), studying the effect of the angiotensin II receptor antagonist irbesartan on progression of renal disease and mortality in type II diabetic patients with overt nephropathy and hypertension. Here we report the study design and baseline patient characteristics.
Methods. To qualify, hypertensive type II patients, age 30–70 years, must have a 24 h urinary protein excretion of >900 mg and a serum creatinine 90–265 µmol/l (1.0–3.0 mg/dl) in women and 110–265 µmol/l (1.2–3.0 mg/dl) in men. Three treatment arms include irbesartan, placebo and amlodipine, with every attempt made to achieve similar blood pressure levels in all treatment arms. A total of 1650 patients will be enrolled utilizing ~225 clinics worldwide. The primary outcome measure is time to event to the composite end-point of doubling of serum creatinine, end-stage renal disease or death. The secondary outcome measure is time to composite end-point of fatal or non-fatal cardiovascular events. The average length of patient follow-up is expected to be ~36 months.
Results. The baseline characteristics of the study subjects are: age 59±8 years, duration of diabetes 15±9 years, height 168±11 cm (5 ft 6 in), weight 87±19 kg (192 lb), body mass index 31±7 kg/m2, blood pressure 156±18 mmHg/85±11 mmHg, serum creatinine 150±53 µmol/l (1.7±0.6 mg/dl), creatinine clearance 66±34 ml/min and 24 h urine protein 4.0±3.5 g/day.
Keywords: angiotensin II receptor antagonist; diabetic nephropathy; renoprotection; type II diabetes
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Shlipak and C. Stehman-Breen Observational Research Databases in Renal Disease J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3477 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Friedman, L. G. Hunsicker, J. Selhub, A. G. Bostom, and for the Collaborative Study Group Total Plasma Homocysteine and Arteriosclerotic Outcomes in Type 2 Diabetes with Nephropathy J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3397 - 3402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pohl, S. Blumenthal, D. J. Cordonnier, F. De Alvaro, G. DeFerrari, G. Eisner, E. Esmatjes, R. E. Gilbert, L. G. Hunsicker, J. B. L. de Faria, et al. Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3027 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Berl, L. G. Hunsicker, J. B. Lewis, M. A. Pfeffer, J. G. Porush, J.-L. Rouleau, P. L. Drury, E. Esmatjes, D. Hricik, M. Pohl, et al. Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2170 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Lewis and J. B. Lewis ACE Inhibitors versus Angiotensin Receptor Blockers in Diabetic Nephropathy: Is There a Winner? J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1358 - 1360. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Palmer, L. Annemans, S. Roze, M. Lamotte, R. A. Rodby, and D. J. Cordonnier An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2059 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Weber Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 62 - 73. [Abstract] [PDF]
|
|
|
|
|
|
K. Kanasaki, D. Koya, T. Sugimoto, M. Isono, A. Kashiwagi, and M. Haneda N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Inhibits TGF-{beta}-Mediated Plasminogen Activator Inhibitor-1 Expression via Inhibition of Smad Pathway in Human Mesangial Cells J. Am. Soc. Nephrol., April 1, 2003; 14(4): 863 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Berl, L. G. Hunsicker, J. B. Lewis, M. A. Pfeffer, J. G. Porush, J.-L. Rouleau, P. L. Drury, E. Esmatjes, D. Hricik, C. R. Parikh, et al. Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy Ann Intern Med, April 1, 2003; 138(7): 542 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Lewis, L. G. Hunsicker, W. R. Clarke, T. Berl, M. A. Pohl, J. B. Lewis, E. Ritz, R. C. Atkins, R. Rohde, I. Raz, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes N. Engl. J. Med., September 20, 2001; 345(12): 851 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A Swift and G. A MacGregor Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 170 - 173. [PDF]
|
|
|
|
|
|
M. Weber Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2_suppl): S12 - S16. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Ruilope RAS blockade: new possibilities in the treatment of complications of diabetes Heart, September 1, 2000; 84(90001): 32i - 34. [Full Text]
|
|